top-banner

NEWS ROOM

Medicover Genetics featured in GenomeWeb for advancing MRD diagnostics

26 June 2025, Medicover Genetics was recently profiled in GenomeWeb for its pioneering work in minimal residual disease (MRD) diagnostics. The article covers our presentation at the 2025 ASCO Annual Meeting, where we shared early results from the DART trial in collaboration with Oslo University Hospital.

Our MRD platform, developed entirely in-house, utilizes a hybrid capture-based liquid biopsy to detect circulating tumor DNA (ctDNA) across a 293-gene panel. The test is designed to support real-time, non-invasive monitoring of cancer progression and response to treatment.

"The initial results were very promising," said Dr. Stefan Christoph Mehrle, Head of Business Unit Genetics. "With relatively few players in Europe developing MRD or liquid biopsy in general we were in a good position to take this on and tailor it to European needs,

In the DART trial, our assay achieved a 92 percent baseline ctDNA detection rate. Early findings suggest that the presence of ctDNA during treatment may be a significant predictor of progression-free and overall survival, pointing to its potential as a molecular biomarker for guiding therapy decisions.

This recognition by GenomeWeb affirms our commitment to enabling more precise, data-driven oncology care through robust, scalable diagnostics.

Read the full article on GenomeWeb (subscription required).

OUR NETWORK